Insider · CIK 0001760020
Theresa Heggie
Files at BCRX (BIOCRYST PHARMACEUTICALS INC). First filing Jun 14, 2024, latest Mar 24, 2026.
In brief
Theresa Heggie files SEC Form 4 as director at BCRX (BIOCRYST PHARMACEUTICALS INC). Since Jun 14, 2024, Theresa Heggie has reported 0 open-market buys worth $0 and 3 open-market sells worth $1.1M, the latest filed on Mar 24, 2026.
A track record needs three past buys with six months of prices behind them; Theresa Heggie has 0, so none is measured yet.
The newest scored trade: sold $505k of BCRX on Mar 20, 2026, filed Mar 24, 2026, scored 36 (weak). In the last 12 months: 0 buys worth $0 and 1 sell worth $505k.
Where the trades landed
Last year at the company this insider has traded most, with each buy and sell on the bar it happened.
BCRX: BIOCRYST PHARMACEUTICALS INC
Daily candles, adjusted for splits and dividends. Green arrows are insider buys, red are sells, sized by value. Click a marked bar to open the signal.Charts by TradingView Lightweight Charts™
Signals
This insider’s open-market buys and sells, scored.
| Score | Company | Value | Holdings | Price context | Filed |
|---|---|---|---|---|---|
| 36Weak | BIOCRYST PHARMACEUTICALS INC | $505k 49,933 shares | -43% | +55% from low-13% from high | |
| 39Weak | BCRXsell BIOCRYST PHARMACEUTICALS INC | $596k 70,000 shares | -52% | +33% from low-24% from high | |
| 41Moderate | BIOCRYST PHARMACEUTICALS INC | $41k 6,698 shares | -11% | +49% from low-23% from high |
Planned sales
Form 144 notices this insider filed before selling restricted or control stock, newest first.
| Filed | Company | Shares | Value | Sale date | Past 3 months |
|---|---|---|---|---|---|
| Mar 20, 2026 | BCRX BIOCRYST PHARMACEUTICALS INC | 49,933 0.02% of outstanding | $505k | Mar 20, 2026 | none |
| Aug 13, 2025 | BCRX BIOCRYST PHARMACEUTICALS INC | 70,000 0.03% of outstanding | $596k | Aug 13, 2025 | none |
| Jun 14, 2024 | BCRX BIOCRYST PHARMACEUTICALS INC | 6,698 0.00% of outstanding | $41k | Jun 14, 2024 | none |
Transactions
Every row this insider has filed, 18 in all, newest first.
| Date | Company | Transaction | Shares | Price | Value | Holdings after | Filed |
|---|---|---|---|---|---|---|---|
| Jun 11, 2026 | BCRX BIOCRYST PHARMACEUTICALS INC | AGrant or award Common Stock | +15,294 | $0.00 | $0 | 80,646 | Jun 15, 2026 |
| Jun 11, 2026 | BCRX BIOCRYST PHARMACEUTICALS INC | AGrant or award Automatic Stock Option Grantderivative | +33,540 | $0.00 | $0 | 33,540 | Jun 15, 2026 |
| Mar 20, 2026 | BCRX BIOCRYST PHARMACEUTICALS INC | MOption exercise Common Stock | +49,933 | $6.30 | $315k | 115,285 | Mar 24, 2026 |
| Mar 20, 2026 | BCRX BIOCRYST PHARMACEUTICALS INC | SOpen-market sale Common Stock | -49,933 | $10.11 | $505k | 65,352 | Mar 24, 2026 |
| Mar 20, 2026 | BCRX BIOCRYST PHARMACEUTICALS INC | MOption exercise Automatic Stock Option Grantderivative | -49,933 | $0.00 | $0 | 0 | Mar 24, 2026 |
| Aug 13, 2025 | BCRX BIOCRYST PHARMACEUTICALS INC | MOption exercise Common Stock | +30,000 | $2.91 | $87k | 95,352 | Aug 15, 2025 |
| Aug 13, 2025 | BCRX BIOCRYST PHARMACEUTICALS INC | MOption exercise Common Stock | +40,000 | $5.41 | $216k | 135,352 | Aug 15, 2025 |
| Aug 13, 2025 | BCRX BIOCRYST PHARMACEUTICALS INC | SOpen-market sale Common Stock | -70,000 | $8.51 | $596k | 65,352 | Aug 15, 2025 |
| Aug 13, 2025 | BCRX BIOCRYST PHARMACEUTICALS INC | MOption exercise Automatic Stock Option Grantderivative | -30,000 | $0.00 | $0 | 0 | Aug 15, 2025 |
| Aug 13, 2025 | BCRX BIOCRYST PHARMACEUTICALS INC | MOption exercise Automatic Stock Option Grantderivative | -40,000 | $0.00 | $0 | 0 | Aug 15, 2025 |
| Jun 12, 2025 | BCRX BIOCRYST PHARMACEUTICALS INC | AGrant or award Common Stock | +12,500 | $0.00 | $0 | 65,352 | Jun 16, 2025 |
| Jun 12, 2025 | BCRX BIOCRYST PHARMACEUTICALS INC | AGrant or award Automatic Stock Option Grantderivative | +27,181 | $0.00 | $0 | 27,181 | Jun 16, 2025 |
| Jun 12, 2024 | BCRX BIOCRYST PHARMACEUTICALS INC | AGrant or award Common Stock | +6,820 | $0.00 | $0 | 59,550 | Jun 14, 2024 |
| Jun 14, 2024 | BCRX BIOCRYST PHARMACEUTICALS INC | SOpen-market sale Common Stock | -6,698 | $6.11 | $41k | 52,852 | Jun 14, 2024 |
| Jun 12, 2024 | BCRX BIOCRYST PHARMACEUTICALS INC | AGrant or award Automatic Stock Option Grantderivative | +49,933 | $0.00 | $0 | 49,933 | Jun 14, 2024 |
| May 31, 2024 | BCRX BIOCRYST PHARMACEUTICALS INC | AGrant or award Common Stock | +870 | $6.46 | $5,620 | 52,730 | Jun 3, 2024 |
| Feb 29, 2024 | BCRX BIOCRYST PHARMACEUTICALS INC | AGrant or award Common Stock | +999 | $5.63 | $5,624 | 51,860 | Mar 4, 2024 |
| Nov 30, 2023 | BCRX BIOCRYST PHARMACEUTICALS INC | AGrant or award Common Stock | +956 | $5.88 | $5,621 | 50,861 | Dec 1, 2023 |
Questions about Theresa Heggie
Answered from the filings on this page, as of the latest one.
Is Theresa Heggie buying or selling?
In the last 12 months Theresa Heggie reported 0 open-market buys worth $0 and 1 open-market sell worth $505k on SEC Form 4; the latest was sold $505k of BCRX on Mar 20, 2026. Grants, option exercises and tax withholding are not counted.
How did Theresa Heggie's past buys perform?
Not measured yet. InsiderTell needs three past buys with six months of prices to publish a track record, and Theresa Heggie has 0.
Where does Theresa Heggie file Form 4?
Theresa Heggie has filed Form 4 at BCRX (BIOCRYST PHARMACEUTICALS INC). A Form 4 is required of officers, directors and holders of more than 10% of a share class within two business days of a trade.
Not investment advice. Scores and forward returns are decision support built from public SEC filings and past prices; they describe what happened after comparable filings, not what will happen after this one. Do your own research and size your risk.